Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating adding berzosertib to standard carboplatin/gemcitabine and to pembrolizumab for patients with advanced squamous cell no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Berzosertib (M6620, VX-970) (berzosertib)
• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-24